Canada · Delayed Price · Currency is CAD Vaxil Bio Statistics
Total Valuation
Vaxil Bio has a market cap or net worth of CAD 916,325. The enterprise value is -295,676.
| Market Cap | 916,325 |
| Enterprise Value | -295,676 |
Important Dates
The next estimated earnings date is Thursday, June 4, 2026.
| Earnings Date | Jun 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxil Bio has 3.98 million shares outstanding. The number of shares has increased by 14.84% in one year.
| Current Share Class | 3.98M |
| Shares Outstanding | 3.98M |
| Shares Change (YoY) | +14.84% |
| Shares Change (QoQ) | +27.63% |
| Owned by Insiders (%) | 5.61% |
| Owned by Institutions (%) | n/a |
| Float | 3.76M |
Valuation Ratios
The trailing PE ratio is 1.50.
| PE Ratio | 1.50 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.61 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.94
| Current Ratio | 35.94 |
| Quick Ratio | 35.94 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 50.89% and return on invested capital (ROIC) is -14.06%.
| Return on Equity (ROE) | 50.89% |
| Return on Assets (ROA) | -13.52% |
| Return on Invested Capital (ROIC) | -14.06% |
| Return on Capital Employed (ROCE) | -17.01% |
| Weighted Average Cost of Capital (WACC) | -0.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.12% in the last 52 weeks. The beta is -0.92, so Vaxil Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.92 |
| 52-Week Price Change | -6.12% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.38 |
| Relative Strength Index (RSI) | 60.74 |
| Average Volume (20 Days) | 5,872 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -214,000 |
| Pretax Income | 484,000 |
| Net Income | 485,000 |
| EBITDA | n/a |
| EBIT | -214,000 |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
The company has 1.21 million in cash and n/a in debt, with a net cash position of 1.21 million or 0.30 per share.
| Cash & Cash Equivalents | 1.21M |
| Total Debt | n/a |
| Net Cash | 1.21M |
| Net Cash Per Share | 0.30 |
| Equity (Book Value) | 1.26M |
| Book Value Per Share | 0.32 |
| Working Capital | 1.26M |
Cash Flow
| Operating Cash Flow | -267,000 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vaxil Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.84% |
| Shareholder Yield | -14.84% |
| Earnings Yield | 52.93% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 15, 2025. It was a reverse split with a ratio of 0.02.
| Last Split Date | May 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |